Related Experiment Videos

Inoculated mouse model of Pneumocystis carinii pneumonia

M S Bartlett1, S F Queener, M M Durkin

  • 1Department of Pathology, Indiana University School of Medicine, Indianapolis 46202-5250.

The Journal of Protozoology
|November 1, 1991
PubMed

Insights

A new mouse model for Pneumocystis carinii infection was developed. This model effectively shows drug efficacy for treating Pneumocystis pneumonia (PCP).

Area of Science:

  • Medical research
  • Infectious diseases
  • Pharmacology

Background:

  • Pneumocystis carinii pneumonia (PCP) is a significant opportunistic infection.
  • Existing animal models for studying PCP are often costly or require substantial drug quantities.

Purpose of the Study:

  • To develop a cost-effective and efficient transtracheal mouse model for Pneumocystis carinii infection.
  • To establish a reliable animal model for evaluating therapeutic and prophylactic drugs against PCP.

Main Methods:

  • BALB/c mice, confirmed free of latent P. carinii, were transtracheally inoculated.
  • Infectivity scores were compared between untreated infected mice and those treated with trimethoprim/sulfamethoxazole (50/250 mg/kg).

Main Results:

  • Untreated inoculated mice exhibited a mean infectivity score of 4.1.
  • Trimethoprim/sulfamethoxazole treated mice showed a significantly lower mean infectivity score of 0.1, representing a four-log difference.
  • The mouse model provides a viable source of P. carinii organisms.

Conclusions:

  • The developed transtracheal mouse model is effective for studying P. carinii infections.
  • This model offers a less expensive and lower-drug-requirement alternative to rat models for PCP research.
  • It serves as a valuable tool for assessing drug efficacy in PCP therapy and prophylaxis.

Related Concept Videos